EUCTR2005-005697-71-IT进行中（未招募）不适用
?Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF?PFM): A Phase 3/4, prospective, controlled, randomized, multi-center Study to compare the efficacy and safety of continous infusion (CI) versus intermittent bolus infusion (BI) in subjects With Severe Or Moderately Severe Hemophilia A undergoing unilateral primary total knee replacement? - Advate Randomized Surgery Study
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.The subject or subject?s legally authorized representative has provided signed informed consent 2.The subject is within 18 to 70 years of age, 3. The subject is suffering from severe to moderately severe Haemophilia A (basal level of factor VIII ≤2% of normal) at screenig.A subgroup of 15 subjects in each group will show a basal level of factor VIII <1% of normal. 4.The aPTT must be within the range of normal after administration of F VIII concentrate, ad determined in the preoperative pharmacokinetic evaluation, or as documented in the medical history, if available. 5 The subject is scheduled to undergo an elective unilateral primary total knee replacement (with cemented or uncemented prothesis) 6. The subject has a documented history of at least 150 exposure days to factor VIII concentrates, before entering the study. 6.HIV positive subjects must be immunocompetent as determined with a CD4 count≥ 400 cells/mm³ (CD4 at screening), but HIV negative subjects with CD count <400 qualify, if immunocompetency is documented. 8. The subject has a life expectancy of at least 28 days from the day of surgery
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. The subject has an history of factor VIII inhibitors or a detectable factor VIII inhibitors at screening with a titer ≥ 0,4 BU; 2.The subject has an history of factor VIII inhibitors with a titer ≥ 0,4 BU(by Nijmegen assay)or ≥0,5 BU (by Bethesda assay)at any time prior to screening 3. The subject is scheduled to undergo any other current minor or major surgery during the course of the study.The placement of a central venous lines and the performance of fine needle aspiration biopsies are permitted; 4.Excluding hemophilia-related physical impairments, the subject is assigned to NYHA≥III according to New York Heart Association classification. 5. The subject with an abnormal renal function (serum creatinine >1.5mg/dL), 6. an active hepatic disease( [ALT]or [AST] levels >5 times the upper limit of normal), 7. a severe chronic liver disease (as evidenced by but not limited to INR >1.4, hypoalbuminemia,portal vein hypertansion, including presence of otherwise unexplained splenomegaly and history of esophageal varices, 9.The subject is currently receiving or scheduled to receive an immunomodulating drug other than antiretroviral chemotherapy; 10.a known hypersensitivity to mouse or hampster proteins. 11.The subject has received another investigational drug within 30 days prior to the screening and /or is scheduled to recieve additional investigational drug during the course of the trial in the context of another investigational drug study. 12.The subject is identified by the investigator as being unable or unwilling to cooperate with the study procedures.
研究者
相似试验
进行中（未招募）
1 期
The main goal of the study is to compare the safety and effectiveness of administering ADVATE using either continuous infusion or single, large dose infusions during and post surgery for patients requiring major orthopedic surgeryEUCTR2005-005697-71-SEBaxter Innovations GmbH21
进行中（未招募）
不适用
The main goal of the study is to compare the safety and effectiveness of administering ADVATE using either continuous infusion or single, large dose infusions during and post surgery for patients requiring major orthopedic surgeryEUCTR2005-005697-71-PLBaxalta Innovations GmbH21
进行中（未招募）
1 期
The main goal of the study is to compare the safety and effectiveness of administering ADVATE using either continuous infusion or single, large dose infusions during and post surgery for patients requiring major orthopedic surgerySubjects with Severe or Moderately Severe Hemophilia A (baselinefactor VIII (FVIII) level <= 2% of normal) hemophilia A undergoing major orthopedic surgeryMedDRA version: 17.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850EUCTR2005-005697-71-BEBaxter Innovations GmbH72
进行中（未招募）
不适用
The main goal of the study is to compare the safety and effectiveness of administering ADVATE using either continuous infusion or single, large dose infusions during and post surgery for patients requiring major orthopedic surgeryEUCTR2005-005697-71-HUBaxter Innovations GmbH21
进行中（未招募）
不适用
The main goal of the study is to compare the safety and effectiveness of administering ADVATE using either continuous infusion or single, large dose infusions during and post surgery for patients requiring major orthopedic surgerySubjects with Severe or Moderately Severe Hemophilia A (baselinefactor VIII (FVIII) level <= 2% of normal) hemophilia A undergoing major orthopedic surgeryMedDRA version: 18.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850EUCTR2005-005697-71-ATBaxalta Innovations GmbH21